Testing ER-Beta Agonist Synergy with B7-H1 and mTOR Inhibitors as Novel and Effective Treatments for Ovarian Cancer
Abstract
alphaB7-H1 immunotherapy and ER agonist therapy as single agents were ineffective to treat large tumor volume ovarian cancer in the ID8 mouse model. Using ERbeta KO and B7-H1 KO mice we showed that poor treatment responses were not due to host B7-H1 or ERbeta signals. The combination of alphaB7-H1 plus the ERbeta agonist LY was modestly effective in large tumor volume disease in the model, but the LY caused some toxicities seen as cold paws that could be from compromised blood flow. We found that tumor B7-H1 signals can alter ERbeta signals, seen as reduced ERbeta-dependent VEGF production, which could play a role in treatment efficacy. Work to investigate treatment effects in lower tumor burden and with addition of mTOR inhibitors is underway.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2016
- Accession Number
- AD1044916
Entities
People
- Ratna K Vadlamudi
- Tyler J Curiel
Organizations
- University of Texas at San Antonio